The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Different anti-HCV profiles of statins and their potential for combination therapy with interferon
Open accessAbstract
We recently developed a genome-length hepatitis C virus (HCV) RNA replication system (OR6) with luciferase as a reporter. The OR6 assay system has enabled prompt and precise quantification of HCV RNA replication. Pegylated interferon (IFN) and ribavirin combination therapy is the world standard for chronic hepatitis C, but its effectiveness is limited to about 55% of patients. Newer therapeutic approaches are needed. In the present study, we used the OR6 assay system to evaluate the anti-HCV activity of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, called statins, and their effects in combination with IFN-α. Five types of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) were examined for their anti-HCV activities. Fluvastatin exhibited the strongest anti-HCV activity (IC50: 0.9 μmol/L), whereas atorvastatin and simvastatin showed moderate inhibitory effects. However, lovastatin, reported recently as an inhibitor of HCV replication, was shown to exhibit the weakest anti-HCV activity. The anti-HCV activities of statins were reversed by the addition of mevalonate or geranylgeraniol. Surprisingly, however, pravastatin exhibited no anti-HCV activity, although it worked as an inhibitor for HMG-CoA reductase. The combination of IFN and the statins (except for pravastatin) exhibited strong inhibitory effects on HCV RNA replication. In combination with IFN, fluvastatin also exhibited a synergistic inhibitory effect. In conclusion , statins, especially fluvastatin, could be potentially useful as new anti-HCV reagents in combination with IFN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178
Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line
Lohmann, V., Körner, F., Koch, J.-O., Herian, U., Theilmann, L., & Bartenschlager, R. (1999) · Science · doi:10.1126/science.285.5424.110 · Cited by 2,814
Production of infectious hepatitis C virus in tissue culture from a cloned viral genome
Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K., Habermann, A., Kräusslich, H.-G., Mizokami, M., et al. (2005) · Nature Medicine · doi:10.1038/nm1268 · Cited by 2,754
Complete Replication of Hepatitis C Virus in Cell Culture
Lindenbach, B. D., Evans, M. J., Syder, A. J., Wölk, B., Tellinghuisen, T. L., Liu, C. C., Maruyama, T., Hynes, R. O., Burton, D. R., McKeating, J. A., et al. (2005) · Science · doi:10.1126/science.1114016 · Cited by 2,238
Robust hepatitis C virus infection in vitro
Zhong, J., Gastaminza, P., Cheng, G., Kapadia, S., Kato, T., Burton, D. R., Wieland, S. F., Uprichard, S. L., Wakita, T., & Chisari, F. V. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503596102 · Cited by 1,709
Mechanism of action of interferon and ribavirin in treatment of hepatitis C
Feld, J. J., & Hoofnagle, J. H. (2005) · Nature · doi:10.1038/nature04082 · Cited by 992
Identification of a Novel Gene Family Encoding Human Liver-specific Organic Anion Transporter LST-1
Abe, T., Kakyo, M., Tokui, T., Nakagomi, R., Nishio, T., Nakai, D., Nomura, H., Unno, M., Suzuki, M., Naitoh, T., et al. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.24.17159 · Cited by 543
Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids
Kapadia, S. B., & Chisari, F. V. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409834102 · Cited by 511
Ikeda, M., Yi, M., Li, K., & Lemon, S. M. (2002) · Journal of Virology · doi:10.1128/jvi.76.6.2997-3006.2002 · Cited by 383
Self-citationYe, J., Wang, C., Sumpter, R., Brown, M. S., Goldstein, J. L., & Gale, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2237238100 · Cited by 366
Cited by
Statins and the Risk of Hepatocellular Carcinoma in Patients With Hepatitis B Virus Infection
Tsan, Y.-T., Lee, C.-H., Wang, J.-D., & Chen, P.-C. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.0917 · Cited by 294
El–Serag, H. B., Johnson, M. L., Hachem, C., & Morgana, R. O. (2009) · Gastroenterology · doi:10.1053/j.gastro.2009.01.053 · Cited by 291
Cholesterol biosynthesis modulation regulates dengue viral replication
Rothwell, C., LeBreton, A., Young Ng, C., Lim, J. Y. H., Liu, W., Vasudevan, S., Labow, M., Gu, F., & Gaither, L. A. (2009) · Virology · doi:10.1016/j.virol.2009.03.025 · Cited by 269
Abnormalities of lipid metabolism in hepatitis C virus infection
Negro, F. (2010) · Gut · doi:10.1136/gut.2009.192732 · Cited by 162
Sun, H., & Singh, N. (2009) · Clinical Infectious Diseases · doi:10.1086/597039 · Cited by 65
Metadata
- Authors
- Ikeda, M., Abe, K.-I., Yamada, M., Dansako, H., Naka, K., & Kato, N.
- Venue
- Hepatology
- Published
- 2006-07
- Volume
- 44
- Issue
- 1
- Pages
- 117-125
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2155820299
- Cited by
- 313
- References
- 21
- FWCI
- 18.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Different anti-HCV profiles of statins and their potential for combination therapy with interferon. https://app.cochat.ai/papers/10.1002/hep.21232
- The paper
- Ikeda, M., Abe, K.-I., Yamada, M., Dansako, H., Naka, K., & Kato, N. (2006). Different anti-HCV profiles of statins and their potential for combination therapy with interferon. Hepatology. https://doi.org/10.1002/hep.21232
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
